A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
about
DNA Repair and Cytokines: TGF-β, IL-6, and Thrombopoietin as Different Biomarkers of RadioresistanceRecent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapyTrial Watch-Immunostimulation with cytokines in cancer therapyThe era of bioengineering: how will this affect the next generation of cancer immunotherapy?Treatment with anti-IL-6 receptor antibody prevented increase in serum hepcidin levels and improved anemia in mice inoculated with IL-6-producing lung carcinoma cellsA phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancerProteomic profiling of the cancer cell secretome: informing clinical research.Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy.Vaccines for established cancer: overcoming the challenges posed by immune evasion.Pharmacological and immunological targeting of tumor mesenchymalization.Targeting cancer-related inflammation in the era of immunotherapy.Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment.High mRNA expression level of IL-6R was associated with better prognosis for patients with ovarian cancer: a pooled meta-analysis.IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.[Influence of therapy on risk of cancer in rheumatoid arthritis. Pathophysiological principles].Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy.Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer.Ascites-derived IL-6 and IL-10 synergistically expand CD14+HLA-DR-/low myeloid-derived suppressor cells in ovarian cancer patients.Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity.CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer.Targeting the IL-6/JAK/STAT3 signalling axis in cancer.CGI-99 promotes breast cancer metastasis via autocrine interleukin-6 signaling.Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic.Epithelial-mesenchymal transition and inflammation at the site of the primary tumor.Trial Watch: Immunostimulation with recombinant cytokines for cancer therapySystematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer
P2860
Q26738556-DFAB1D32-3338-4C83-88E5-8E3300A55223Q26745710-7A777F45-94F9-4352-AD6F-5CEE35386781Q28078725-15EDF4EB-3635-4BD6-BFC6-EFE7FFD16786Q33815087-39BA66E1-3ECC-4018-A029-05C07C214139Q35986531-FB77CEEB-A92A-43C9-A1C7-BAC049136586Q36544827-51CB3EE5-7A4C-4442-994E-34CC9185FBA8Q37276254-1D73BEBF-996C-4C4A-AB25-38B0EF7B3170Q38659528-5FD4F799-9681-4EEA-A0D9-846D55BAC63BQ38659916-E0D8D2C3-0669-48CC-9FA5-6B600ABE42D0Q38769021-5326F135-B9DA-46AB-9990-D6AC54258D6BQ39029043-BFCDB2B9-3229-4FF9-8811-9486F5F97FAAQ39044981-12968326-D197-49F2-A8BD-4EE3F766E382Q39390630-372A354E-3117-473C-920F-EAF6B9C5CD53Q40077912-1727AED0-7BCE-41C5-AD24-482FEBBC96D9Q40503359-E9D5A123-12DB-4AAC-AF91-DA5175C311B4Q40826525-746C99C5-9C41-4D61-BA84-69C803B7FC2AQ42288627-AC9023A8-B3C7-4A73-AF9C-05E2F02A9B57Q42369233-384A0133-60CE-45BB-BF5B-AF186F54C899Q45813459-71957748-395A-4383-97DE-9510277ABBF8Q48090319-71D449FE-AC03-4C08-AFB2-DEB3627F7E34Q49888066-D7D8C63B-E408-496D-8F9C-282CC706AF39Q50191433-350070E5-4FC2-4841-B6C7-24AA76460C20Q51150626-BC4C60E6-1BDA-48B4-894B-E806D9FC20B3Q51825149-8197A909-6EB4-424E-8B9C-87F782CF7ADFQ52540247-FEF54C76-9959-4666-A8F6-CE2A340D78BEQ56892924-24BC26B8-317C-4F0B-A357-91D04E98B938Q57115352-1CAC0FB6-F4BB-480E-8BB9-97EACFA4A108
P2860
A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
A phase I trial combining carb ...... ent epithelial ovarian cancer.
@en
A phase I trial combining carb ...... ent epithelial ovarian cancer.
@nl
type
label
A phase I trial combining carb ...... ent epithelial ovarian cancer.
@en
A phase I trial combining carb ...... ent epithelial ovarian cancer.
@nl
prefLabel
A phase I trial combining carb ...... ent epithelial ovarian cancer.
@en
A phase I trial combining carb ...... ent epithelial ovarian cancer.
@nl
P2093
P2860
P921
P356
P1433
P1476
A phase I trial combining carb ...... rent epithelial ovarian cancer
@en
P2093
A K L Reyners
A R van Erkel
E M Dijkgraaf
G G Kenter
H W Nijman
J J M van der Hoeven
M I E van Poelgeest
M J P Welters
R Goedemans
S H van der Burg
P2860
P304
P356
10.1093/ANNONC/MDV309
P577
2015-07-27T00:00:00Z